Dermal Grafts Market: By Graft Type (Autologous, Isogeneic, Allogeneic, Xenogeneic, Prosthetic) By Graft Thickness (Split-Thickness, Full-Thickness, Composite Graft) By Applications (Extensive Wound, Burns, Infection, Skin Cancers, Others) By Equipment (Dermatome (Knives Dermatomes, General Surgical Instruments, Consumables, Electric Dermatomes, Air Dermatomes) By End Users (Hospitals, Ambulatory Surgical Centers, Dermatology Clinics, Others) and By Geography  

Dermal Grafts Market poised to grow at a CAGR of 13% during 2023 to 2029. Dermal grafting is the procedure in which the part of the skin is replaced with the skin from other parts of the body. A dermal graft is used to replace damaged or missing skin or to provide a temporary wound covering. Dermal grafts market is performed or recommended for skin infections, injury, deep burns, skin cancer, pressure ulcers and reconstructive surgeries. There are two types of skin grafts Viz. the split-level thickness and full thickness. Split-level thickness includes removal of dermal and epidermal layers of the skin and full-thickness grafts involve removal of muscles and blood vessels. Patients with deeper tissue loss need a full-thickness skin graft to cover the wound. This requires an entire thickness of skin from the donor site, not just the top two layers. Dermal grafts market is driven by rise in the incidence of burns, accidents and surgeries requiring removal of skin. In addition factors such as skin loss due to cancer and infection are boosting the demand for dermal grafts. According to Skin Cancer Foundation, each year over 5.4 Mn cases of non-melanoma skin cancer are reported and over 3.3 Mn people are treated for the same in the U.S. However, complications of dermal grafts such as infection, pain, high cost of the procedure, and tissue rejection are some of the factors hindering the growth of the global dermal grafts market.

Dermal Grafts Market Key Developments:

• In October 2015, Galil Medical launched two cryoablation (killing of cancer cells with extreme cold) products, IcePearl 2.1 CX and IceFORCE 2.1 CX Cryoablation Needles.
• In August 2016, Mallinckrodt plc., a leading speciality pharmaceutical company, acquired Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products, such as stratagrafs regenerative skin tissue and a technology platform for genetically enhanced skin tissues.